Skip to main content

Lipid Metabolism Disorder

1
Pipeline Programs
4
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Luye Pharma
Luye PharmaChina - Shanghai
1 program
1
XueZhiKangPhase 11 trial
Active Trials
NCT02603770Completed20Est. Feb 2016
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
Lipid Management in Clinical Practice (MK-0524A-115)N/A
MSD
MSDIreland - Ballydine
1 program
Lipid Management in Clinical Practice (MK-0524A-115)N/A1 trial
Active Trials
NCT01071278Completed2,390Est. Feb 2011
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
Lipid Management in Clinical Practice (MK-0524A-115)N/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Luye PharmaXueZhiKang
MSDLipid Management in Clinical Practice (MK-0524A-115)

Clinical Trials (2)

Total enrollment: 2,410 patients across 2 trials

Compare Pharmacokinetic(PK) Profiles of XZK vs Lovastatin in Healthy Male Volunteers

Start: Nov 2015Est. completion: Feb 201620 patients
Phase 1Completed
NCT01071278MSDLipid Management in Clinical Practice (MK-0524A-115)

Lipid Management in Clinical Practice (MK-0524A-115)

Start: Oct 2009Est. completion: Feb 20112,390 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.